A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

被引:45
|
作者
Pantuck, A. J. [1 ]
Pettaway, C. A. [2 ]
Dreicer, R. [3 ]
Corman, J. [4 ]
Katz, A. [5 ]
Ho, A. [5 ]
Aronson, W. [1 ,6 ]
Clark, W. [7 ]
Simmons, G. [8 ]
Heber, D. [1 ,9 ]
机构
[1] Univ Calif Los Angeles, Dept Urol, Inst Urol Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] Winthrop Univ Hosp, Garden City, NY USA
[6] VA Med Ctr Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[7] Alaska Clin Res Ctr, Anchorage, AK USA
[8] Five Valleys Urol, Missoula, MT USA
[9] Univ Calif Los Angeles, Dept Med & Clin Nutr, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
MANGANESE SUPEROXIDE-DISMUTASE; FACTOR-KAPPA-B; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; PHASE-II; GROWTH; CARCINOGENESIS; RADIATION; JUICE; RISK;
D O I
10.1038/pcan.2015.32
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The primary objective of this study was to compare the effects of pomegranate juice on PSA doubling times (PSADT) in subjects with rising PSA levels after primary therapy for prostate cancer. METHODS: Double-blind, placebo-controlled multi-institutional study, evaluated the effects of pomegranate liquid extract on serum PSA levels. The primary end point of this study was change in serum PSADT. Additional secondary and exploratory objectives were to evaluate the safety of pomegranate juice and to determine the interaction of manganese superoxide dismutase (MnSOD) AA genotype and pomegranate treatment on PSADT. RESULTS: One-hundred eighty-three eligible subjects were randomly assigned to the active and placebo groups with a ratio of 2: 1 (extract N = 102; placebo N = 64; juice N = 17). The majority of adverse events were of moderate or mild grade. Median PSADT increased from 11.1 months at baseline to 15.6 months in the placebo group (P < 0.001) compared with an increase from 12.9 months at baseline to 14.5 months in the extract group (P = 0.13) and an increase from 12.7 at baseline to 20.3 in the juice group (P = 0.004). However, none of these changes were statistically significant between the three groups (P > 0.05). Placebo AA patients experienced a 1.8 month change in median PSADT from 10.9 months at baseline to 12.7 months (P = 0.22), while extract patients experienced a 12 month change in median PSADT from 13.6 at baseline to 25.6 months (P = 0.03). CONCLUSIONS: Compared with placebo, pomegranate extract did not significantly prolong PSADT in prostate cancer patients with rising PSA after primary therapy. A significant prolongation in PSADT was observed in both the treatment and placebo arms. Men with the MnSOD AA genotype may represent a group that is more sensitive to the antiproliferative effects of pomegranate on PSADT; however, this finding requires prospective hypothesis testing and validation.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [41] Effect of Dietary Supplementation with a Natural Extract of Sclerocarya birrea on Glycemic Metabolism in Subjects with Prediabetes: A Randomized Double-Blind Placebo-Controlled Study
    Victoria-Montesinos, Desiree
    Sanchez-Macarro, Maravillas
    Gabaldon-Hernandez, Jose Antonio
    Abellan-Ruiz, Maria Salud
    Querol-Calderon, Maria
    Luque-Rubia, Antonio J.
    Bernal-Morell, Enrique
    Avila-Gandia, Vicente
    Lopez-Roman, Francisco Javier
    NUTRIENTS, 2021, 13 (06)
  • [42] Efficacy of Supportive Therapy of Allergic Rhinitis by Stinging Nettle (Urtica dioica) root extract: a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial
    Bakhshaee, Mehdi
    Pour, Amir Hooshang Mohammad
    Esmaeili, Majid
    Azad, Farahzad Jabbari
    Talesh, Ghazal Alipour
    Salehi, Maryam
    Mohajer, Morteza Noorollahian
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2017, 16 : 112 - U246
  • [43] Safety of red ginseng and herb extract complex (RHC) in menopausal women: A randomized, double-blind, placebo-controlled trial
    Hyun, Sun Hee
    Han, Chang-Kyun
    So, Seung-Ho
    Park, Soo Kyung
    Park, Chae-Kyu
    In, Gyo
    Lee, Ji Young
    JOURNAL OF GINSENG RESEARCH, 2022, 46 (04) : 601 - 608
  • [44] The effect of vitamin D on recurrence of uterine fibroids: A randomized, double-blind, placebo-controlled pilot study
    Vahdat, Mansoureh
    Allahqoli, Leila
    Mirzaei, Hossein
    Giovannucci, Edward
    Salehiniya, Hamid
    Mansouri, Ghazal
    Alkatout, Ibrahim
    COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE, 2022, 46
  • [45] Biocurcumin as Radiosensitiser for Cervical Cancer Study (BRACES): A Double-Blind Randomised Placebo-Controlled Trial
    Purbadi, Sigit
    Rustamadji, Primariadewi
    Prijanti, Ani R.
    Sekarutami, Sri Mutya
    Sutrisna, Bambang
    Suyatna, Franciscus D.
    Andrijono, Andrijono
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2020, 2020
  • [46] A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
    Durgam, Suresh
    Chen, Changzheng
    Migliore, Raffaele
    Prakash, Chandran
    Edwards, John
    Findling, Robert L.
    PEDIATRIC DRUGS, 2018, 20 (04) : 353 - 363
  • [47] Tomato Phytonutrients Balance UV Response: Results from a Double-Blind, Randomized, Placebo-Controlled Study
    Groten, Katharina
    Marini, Alessandra
    Grether-Beck, Susanne
    Jaenicke, Thomas
    Ibbotson, Sally H.
    Moseley, Harry
    Ferguson, James
    Krutmann, Jean
    SKIN PHARMACOLOGY AND PHYSIOLOGY, 2019, 32 (02) : 101 - 108
  • [48] Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study
    Brizot, Maria L.
    Hernandez, Wagner
    Liao, Adolfo W.
    Bittar, Roberto E.
    Francisco, Rossana P. V.
    Krebs, Vera L. J.
    Zugaib, Marcelo
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2015, 213 (01) : 82.e1 - 82.e9
  • [49] Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial
    Motamed, Mahsa
    Karimi, Hanieh
    Moghaddam, Hossein Sanjari
    Boroujeni, Sina Taherzadeh
    Sanatian, Zahra
    Hasanzadeh, Alireza
    Ardakani, Mohammad-Reza Khodaei
    Akhondzadeh, Shahin
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2022, 37 (03) : 92 - 101
  • [50] Anthocyanin supplementation in alleviating thrombogenesis in overweight and obese population: A randomized, double-blind, placebo-controlled study
    Thompson, Kiara
    Pederick, Wayne
    Singh, Indu
    Santhakumar, Abishek Bommannan
    JOURNAL OF FUNCTIONAL FOODS, 2017, 32 : 131 - 138